Importantly, the earlier development of tumors in DMBDD-administered Ogg1−/− males and females, mostly malignant lymphomas/leukemias, lung adenocarcinoma and subcutaneous tumors (fibrosarcomas) was the reason for their earlier mortality. Here, OGG1 is linked to leukemia.